An interventional study of Axonics SNM System INS Model 5101 (R20) in Urinary Urge Incontinence (UUI), Urinary Frequency (UF) and Overactive Bladder (OAB), sponsored by Axonics, Inc.. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Axonics, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Urinary Incontinence, Urge with a site in United Kingdom — 1 open to participants now, 3 under way, none of them phase 3. Urinary Incontinence, Urge · United Kingdom.
Among the 15 studies in Urinary Incontinence, Urge with a site in United Kingdom, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 with no phase, and was the 14th registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →1 of the 15 studies in Urinary Incontinence, Urge with a site in United Kingdom is open now. Recruiting first, the newest first:
Amber Therapeutics Ltd · Sites in United Kingdom, Belgium, Netherlands
Ages 22+ · Women only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 86 across 191 interventional studies indexed under Urinary Incontinence, Urge.
Median enrollment 104 across the 14 interventional studies, 27 across the 1 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Axonics, Inc., one of the names counted as Boston Scientific Corporation. Under that name alone:
Axonics, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Boston Scientific Corporation has 6 studies filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
3 of the studies in Urinary Incontinence, Urge with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
| NCT06789406Axonics, Inc.PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB | 2027-01 |
| NCT06885931Amber Therapeutics LtdAugmenting Urinary Reflex Activity Study 4 (Including eXtended Indications) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Urinary Incontinence, Urge with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.
This post-market clinical follow-up (PMCF) is conducted to assess the continued safety, device performance, and clinical benefit of the rechargeable Axonics SNM System INS Model 5101 also referred to as R20.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with the Axonics SNM System Model 5101 and followed up regarding their overactive bladder symptoms.
Device: Axonics SNM System INS Model 5101 (R20)
Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
Performance/Effectiveness - Improvement in Qualify of Life scoring (OAB)
To demonstrate an improvement in Overactive Bladder Quality of Life using the International Consultation of Incontinence Questionnaire Overactive Bladder Qualify of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.
Time frame: 3 months
Adverse event reporting (Safety)
Device related, procedure-related and all serious adverse events
Time frame: 3 months
Performance/Effectiveness - Improvement in Qualify of Life scoring (OAB)
To demonstrate an improvement in Overactive Bladder Quality of Life using the International Consultation of Incontinence Questionnaire Overactive Bladder Qualify of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.
Time frame: 12 months
Performance/Effectiveness - Improvement in Qualify of Life scoring (FI)
Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence. Assessed if participant had a score of ≥6 at baseline.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.